Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Stocks like NVDA, RL, EXPE and COR are seeing price strength and have a high chance of carrying the momentum forward.
COR's $3.6 billion move to take control of OneOncology boosts its pharma-centric strategy and lifts its long-term growth outlook despite a short-term dip.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora's U.S. Healthcare Solutions strength, RCA gains, and raised FY25 guidance underscore its accelerating growth momentum.
Here is how Cencora (COR) and CorMedix (CRMD) have performed compared to their sector so far this year.
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
Cencora, Inc. (COR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Cencora (COR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cencora, Inc. (COR) Presents at Evercore 8th Annual Healthcare Conference Transcript
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.